Portfolio
Clearbridge BioMedics collaborates with research partners to develop medical devices that aid in cancer diagnostics and patient care.
Their product, CTChip, is the next generation non-invasive ‘liquid biopsy’ for cancer detection and is set to change the face of cancer diagnostics and treatment. Their label-free technology does not employ biomarkers to identify circulating tumour cells (CTCs), which are critical components in cancer detection and treatment. Instead, the non-invasive procedure uses biomechanical properties of cells alone, allowing intact and viable CTCs to be isolated and retrieved.